Biological
Vanutide cridificar clinical trials
Also written ACC-001.
- studies test it
- 9
- open now
- 0
- in phase 3
- 0
- first study started
- 2007
How studies write it
Studies that test it under each name
Name
Development codes
Combined with it in one product
Studies by the year they started
9 studies that test it; most in 2009 (3)
| Year | Studies |
|---|---|
| 2007 | 2 |
| 2008 | 1 |
| 2009 | 3 |
| 2010 | 1 |
| 2011 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 2
- 9
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 9 · Other 0
Pfizer (8) · JANSSEN Alzheimer Immunotherapy Research & Development, LLC (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses vanutide cridificar is read from its arms, and is right about nine times in ten.
Testing it · 9
- Long Term Extension Study Evaluating Safety, Tolerability and Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimer's DiseaseCompletedPhase 2PfizerNCT00955409Written as ACC-001(3µg) + QS21
- A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's DiseaseTerminatedPhase 2PfizerNCT00960531Written as ACC-001+ QS21 (3mcg)
- Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Early Alzheimer's DiseaseCompletedPhase 2PfizerNCT01227564Written as ACC-001 3 μg/ QS-21 50 μg
- Safety, Tolerability, And Immunogenicity Study Of ACC-001 In Japanese Subjects With Mild To Moderate Alzheimer's DiseaseCompletedPhase 2PfizerNCT00959192Written as ACC-001
- Study Evaluating Safety, Tolerability, And Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimer's DiseaseCompletedPhase 2PfizerNCT00479557Written as ACC-001 + QS-21
- Study Evaluating ACC-001 in Japanese Patients With Mild To Moderate Alzheimer's DiseaseCompletedPhase 2PfizerNCT00752232Written as ACC-001
- Study Evaluating ACC-001 In Subjects With Mild To Moderate Alzheimer's DiseaseCompletedPhase 2PfizerNCT00498602Written as ACC-001 + QS-21
- Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Mild to Moderate Alzheimer's DiseaseCompletedPhase 2JANSSEN Alzheimer Immunotherapy Research & Development, LLCNCT01284387Written as ACC-001 (vanutide cridificar)
- Long Term Extension Study Evaluating Safety, Tolerability And Immunogenicity Of ACC-001 In Japanese Subjects With Mild To Moderate Alzheimer's DiseaseTerminatedPhase 2PfizerNCT01238991Written as ACC-001
Codes
What other systems call vanutide cridificar · ClinicalTrials.gg INT000355
- MeSH (NLM) C000603458vanutide cridificarOne source NLM
- UNII (FDA) 9HRI13ZIDXVANUTIDE CRIDIFICARConfirmed FDA, NLM, Wikidata
- Wikidata Q106654743vanutide cridificarConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C152829Vanutide CridificarOne source FDA
- DrugBank DB12132One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000603458 | vanutide cridificar | One source NLM |
| UNII (FDA) | 9HRI13ZIDX | VANUTIDE CRIDIFICAR | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q106654743 | vanutide cridificar | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C152829 | Vanutide Cridificar | One source FDA |
| DrugBank | DB12132 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.